Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Inventory: 2017-2024

Historic Inventory for Ptc Therapeutics (PTCT) over the last 8 years, with Dec 2024 value amounting to $23.2 million.

  • Ptc Therapeutics' Inventory rose 47.71% to $52.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.7 million, marking a year-over-year increase of 47.71%. This contributed to the annual value of $23.2 million for FY2024, which is 24.15% down from last year.
  • Ptc Therapeutics' Inventory amounted to $23.2 million in FY2024, which was down 24.15% from $30.6 million recorded in FY2023.
  • Over the past 5 years, Ptc Therapeutics' Inventory peaked at $30.6 million during FY2023, and registered a low of $15.9 million during FY2021.
  • Over the past 3 years, Ptc Therapeutics' median Inventory value was $23.2 million (recorded in 2024), while the average stood at $25.2 million.
  • Its Inventory has fluctuated over the past 5 years, first spiked by 40.21% in 2023, then decreased by 24.15% in 2024.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Inventory stood at $18.7 million in 2020, then declined by 15.19% to $15.9 million in 2021, then soared by 37.54% to $21.8 million in 2022, then surged by 40.21% to $30.6 million in 2023, then declined by 24.15% to $23.2 million in 2024.